John Bridgeman

Chief Scientific Officer Immunokey

Seminars

Wednesday 2nd December 2026
Insights Exchange – What Drives Confidence in Translational Decision Making?
8:50 am
  • Which datasets provide the greatest confidence when progressing a candidate?
  • How can teams determine whether a preclinical signal is meaningful enough to justify investment?
  • What are the biggest barriers to translating promising biology into clinical success?
  • Audience Q&A
Wednesday 2nd December 2026
Evidence – Using Translational Models to Overcome Tumour Antigen Heterogeneity & Improve CAR-T Responses in Solid Tumours
8:30 am
  • Understanding how tumour antigen heterogeneity contributes to resistance and variable patient responses in CAR-T therapy
  • Leveraging translational model systems to evaluate strategies that overcome antigen escape and improve therapeutic durability
  • Applying insights from the CARKey platform to develop more consistent and clinically meaningful responses across diverse patient populations
Dr John Bridgeman, Chief Scientific Officer at Immunokey Ltd, speaker at the 15th Tumour Models Summit London